Stay updated on Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial
Sign up to get notified when there's something new on the Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial page.

Latest updates to the Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial page
- Check2 days agoChange DetectedOn 2026-09-10 the record shows that results have been posted and new sections for Adverse Events, Baseline Characteristics, Contacts/Locations, and Study Status were added (with 2026-08-18 represented as version 53). The prior 2026-05-05 'Results Submitted' entry was removed.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.6.6 is now shown on the page, replacing Revision: v3.6.5. This indicates a minor platform update that does not affect the study content or user interactions.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page’s revision tag updated from Revision: v3.6.4 to Revision: v3.6.5, signaling a minor system update. This change does not affect the study data or history content displayed on the page.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision 3.6.4 was issued, adding new sections such as Adverse Events, Outcome Measures (Results), Baseline Characteristics, Participant Flow, Document Section, References, and Study Status, and the record was returned on 2026-07-23. The update also shows that the Quality Control Review Has Not Concluded and that the previous revision 3.6.3 was removed.SummaryDifference0.8%

- Check73 days agoChange DetectedA new 'Results Submitted' addition is shown and the latest revision is 'Revision: v3.6.3'. The entries 'No Results Posted' and 'Revision: v3.6.2' have been removed.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded a new revision entry Revision: v3.6.2 to the study record history and removed the prior Revision: v3.6.0. This is a minor metadata update to the page’s version history and does not change trial details.SummaryDifference0.1%

Stay in the know with updates to Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial page.